Open-angle glaucoma: tips for earlier detection and treatment selection

Journal of Family Practice, Feb, 2005 by Ahmad A. Aref, Brian P. Schmitt

(22.) Quigley HA. Identification of glaucoma-related visual field abnormality with the screening protocol of frequency doubling technology. Am J Ophthalmol 1998; 125:819-829.

(23.) The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS). The relationship between control intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130:4:429-440.

(24.) Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126:4:487-497.

(25.) Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Kornakoff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Early Manifest Glaucoma Trial Group. Arch Ophthalmol 2003; 121:48-56.

(26.) Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124:544-547.

(27.) Alward WL. Medical management of glaucoma. N Eng J Med 1998; 339:1298-1307.

(28.) Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol 1990; 108:1264-1267.

(29.) Butler P, Mannschreck M, Lin S, Hwang I, Alvarado J. Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol 1995; 113:293-296.

(30.) Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 2% brimonidine. Arch Ophthalmol 1995; 113:77-83.

(31.) Lippa EA, Schuman JS, Higginbotham EJ, et al. MK507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991; 98:308-312.

(32.) Hyong PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000; 59:411-434.

(33.) Avorn J, Glynn RJ, Gurwitz JH, et al. Adverse pulmonary effects of topical beta blockers used in the treatment of glaucoma. J Glaucoma 1993; 2:158-165.

(34.) Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986; 104:197-199.

(35.) Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986. Am J Ophthalmol 1987; 103:512.

(36.) Yogel R, Tipping R, Kudaga SF, Clineschmidt CM. Timolol-Betaxolol Study Group. Changing therapy from timolol to betaxolol: effect on intraocular pressure in selected patients with glaucoma. Arch Ophthalmol 1989; 107:1303-1307.

(37.) Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM; Bimatoprost Circadian IOP Study Group. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004; 49 Suppl 1:S26-S35.

(38.) Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120:1286-1293.